So far, the Chevrolet Spark is the only car in its size class to earn the Insurance Institute for Highway Safety's Top Safety Pick award. Even so, there is inherently greater risk in a car this small, the Institute said.
NEW YORK (CNNMoney) Many of the smallest cars sold in America did very poorly in a challenging crash test conducted by the Insurance Institute for Highway Safety.
Of 11 subcompact and minicars subjected to the Institute's small overlap crash test only one, General Motors' (GM, Fortune 500) Chevrolet Spark, did reasonably well.
Six of the cars earned the Institute's lowest rating of "Poor." Those were the Nissan (NSANF) Versa, Toyota (TM) Prius c, Hyundai Accent, the Mitsubishi Mirage, Chrysler Group's Fiat 500 and the Honda (HMC) Fit. The Mazda2, Kia Rio, Toyota Yaris and Ford (F, Fortune 500) Fiesta were deemed Marginal, the second-worst of four possible ratings. Most of these cars have done well in the Institute's other crash tests and in government tests. The Insurance Institute is a private organization financed by auto insurers.
Bayerische Motoren Werke AG is a German holding company and automobile manufacturer that focuses on the automobile and motorcycle markets. It divides its activities into the three main segments: Automobiles, Motorcycles and Financial Services. It owns three brands: BMW, MINI and Rolls-Royce. Its BMW automobile range encompasses the 1 Series, including three-door, five-door, coupe and convertible models; the 3 Series, including sedan, touring, coupe and convertible models; the 5 Series, available in sedan and touring models; the 6 Series, available as a coupe or convertible; the 7 Series large sedan; the Z4 roadster and coupe; the sports utility vehicles, X3, X5 and X6 and M models, such as M3, M5 and M6. It also offers cars under the MINI brand and motorcycles under the BMW brand. The Rolls-Royce brand offers three luxury cars, Phantom, Coupe and Ghost. It has producing, assembly, service and sales subsidiaries throughout the world. In January 2013, it sold its Husqvarna brand.
Advisors' Opinion: Hot Net Payout Yield Stocks To Invest In 2015: Medtronic Inc (MDT)
Medtronic, Inc. (Medtronic), incorporated on April 23, 1957, is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. In August 2013, Medtronic, Inc. announced the closing of the acquisition of Cardiocom. Effective September 3, 2013, Medtronic Inc acquired a 30% stake in NGC Medical SpA.
Cardiac Rhythm Disease Management
CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. The Company's principal products offered by CRDM business include Implantable Cardiac Pacemakers (Pacemakers), Implantable Cardioverter Defibrillators (ICDs), Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps), AF Products, Diagnostics and Monitoring Devices and Patient Management Tools. The Company's pacemaker systems are compatible with certain magnetic resonance imaging (MRI) machines. This includes the Revo MRI SureScan with United States Food and Drug Administration approval and the Advisa and Ensura MRI SureScan models with Conformite Europeene (CE)! Mark approval. Medtronic also continues to market the Adapta product family, which includes the Adapta, Versa, Sensia, and Relia models.
The Medtronic ICDs is the Protecta family with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures. Devices in the ICD family are the Protecta XT, Protecta, Cardia, and Egida models. Medtronic also continues to market the Secura and Maximo II devices. The Medtronic CRT-Ds is the Protecta family with SmartShock technology, including Protecta XT and Protecta, and the CRT-P devices are Consulta and Syncra. Medtronic also continues to market the Consulta, Cardia, Egida, and Maximo II CRT-D devices. In addition to these devices, Medtronic has an offering of left heart leads and delivery catheters with its Attain family of products. The Company's portfolio of AF products includes the Arctic Front Cardiac CryoAblation Catheter designed to treat paroxysmal AF by performing pulmonary vein isolation. The Company also offers the Reveal XT Insertable Cardiac Monitor, which is designed to identify and quantify episodes of AF. The Reveal DX and Reveal XT Insertable Cardiac Monitors devices are used to record the heart's electrical activity before, during, and after transient symptoms such as syncope and palpitations to help provide a diagnosis. It has a number of patient management tools, such as CareLink, Paceart, and CardioSight Service. CareLink enables patients to transmit data from their pacemaker, ICD, CRT-D, or Insertable Cardiac Monitors using a portable monitor that is connected to a standard telephone line or cellular network using the Medtronic M-Link accessory.
The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc. and Sorin Group.
CardioVascular
CardioVascular is comprised of three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. The Coronary business includes therapies to treat ! coronary ! artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, along with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories. The products offered by its Coronary business include Percutaneous Coronary Intervention (PCI) and Renal Denervation. The Endovascular and Peripheral business is comprised of a range of products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). The Company's products include endovascular stent graft systems, embolic protection systems, and stent systems for the treatment of narrowed iliac arteries. The products offered by the Company's Endovascular and Peripheral business include Endovascular Stent Grafts and Peripheral Vascular Intervention (PVI). The Structural Heart business offers a range of products and therapies to treat a variety of heart valve disorders. The Company's products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The Company's principal products offered by its Structural Heart business include Heart Valves, Transcatheter Heart Valves, Arrested Heart Surgery, Beating Heart Surgery and Surgical Ablation.
The Company competes with Abbott Laboratories, Boston Scientific, and Johnson & Johnson, Cook, Inc., W. L. Gore & Associates, Inc., Endologix, Inc., C.R. Bard, Inc., Edwards LifeSciences Corporation, St. Jude, Terumo Medical Corporation and Sorin Group.
Spinal
The Company's Spinal business develops, manufactures, and markets a range of medical devices and implants used in the treatment of the spine and musculoskeletal system. The Company's products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumours, fractures ! of the sp! ine, and stenosis. The Company's Spinal business also provides biologic solutions for the dental and orthopedic markets. The Company's Spinal products are used in spinal fusion of both the thoracolumbar region, referring to the mid to lower vertebrae, as well as of the cervical region, or upper spine and neck vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and interbody devices, as well as biologics products, primarily bone growth substitutes including bone graft extenders and structural allografts such as dowels and wedges. The products offered by the Company's Spinal business include Thoracolumbar Products, Cervical Products and Biologics Products.
The Company competes with DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. and Johnson & Johnson.
Neuromodulation
The Company's Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. The l products offered by the Company's Neuromodulation business includes Neurostimulators for Chronic Pain, Implantable Drug Delivery Systems, Deep Brain Stimulation (DBS) Systems and Urology, Fecal, & Gastroenterology Devices. The Company's portfolio of products includes the RestoreSensor (rechargeable), with the Company's AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.
DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. The Company's family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). The Company's therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients.
The Company's competes with Boston Scientific, St. Jude., Urologix, Inc. and Allergan.
Diabetes
The Company's Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The products offered by the Company's Diabetes business includes Integrated Diabetes Management Solutions, Professional CGM and CareLink Therapy Management Software. Outside the United States, the Company offers its Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the United States, the Company offers the Paradigm Revel System, which incorporates new CGM features, including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Medtronic offers physicians a Professional CGM product called the iPro CGM and iPro2 Professional CGM. The Company offers Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to helps patients and their health care prov! iders con! trol their diabetes.
The Company competes with DexCom, Inc., Insulet Corporation, Johnson & Johnson and Roche Ltd.
Surgical Technologies
The Company's Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The products offered by the Company's Surgical Technologies business includes ENT, Neurological Technologies, Navigation and Advanced Energy. The ENT products treat diseases and conditions, such as NIM Nerve Monitoring Systems, Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for Meniere's Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive Sleep Apnea. The Neurological Technologies products treat certain neurological disorders and conditions, such as Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.
The Navigation products are used in cranial, spinal, sinus, and orthopedic surgeries, such as the StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging System, and the PoleStar Surgical MRI System. The products make up the Advanced Energy business: PEAK Surgery System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and the Aquamantys System, which uses patented Transcollation technology to ! provide h! aemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.
The Company competes with Gyrus ACMI, Stryker Corporation, Johnson & Johnson, Integra LifeSciences Holdings Corporation, BrainLAB, Inc., GE Healthcare, Siemens Medical Solutions USA, Inc., Philips Medical Systems, Covidien and ArthroCare Corporation.
Advisors' Opinion: - [By Dan Carroll]
Cardiology device makers haven't had much good to report to investors lately. The entire medical device market has struggled with pricing pressures and other hurdles, but the headaches of heart devices -- from mature markets to Europe's financial crush -- have ramped up the pressure on industry firms such as Medtronic (NYSE: MDT ) .
- [By MONEYMORNING.COM]
Recently these deals have been focused on the pharmaceutical and healthcare industries, and stocks in those industries took a dive after the Treasury released its new regulations on Monday. British pharmaceutical giant AstraZeneca Plc. (NYSE ADR: AZN), which had been the target of a failed inversion bid by U.S. drug maker Pfizer Inc. (NYSE: PFE), dropped 3.6%. AbbVie Inc. (NYSE: ABBV), which is involved in a $54 billion deal to buy Irish pharmaceutical giant Shire Plc. (Nasdaq ADR: SHPG), was down 1.9%. Covidien Plc. (NYSE: COV), an Irish company being bought by American medical device maker Medtronic Inc. (NYSE: MDT) was down 3%.
- [By Lauren Pollock]
Medtronic Inc.(MDT) said its fiscal third-quarter earnings fell 23% on a big write-down related to the medical-device maker’s renal denervation program that masked revenue growth. The company narrowed its earnings forecast for the year.
- [By Reuters]
Elise Amendola/AP Pfizer reported lower-than-expected quarterly earnings and revenue, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending its shares down 3 percent. The company said on Tuesday that it earned $2.75 billion, or 38 cents a share, in the first quarter. That compared with $1.79 billion, or 24 cents a share, a year earlier, when it took charges to boost productivity and address legal matters. Excluding special items, Pfizer Inc. (PFE) earned 54 cents a share. Analysts on average expected 55 cents. Revenue fell 9 percent to $13.5 billion, below Wall Street expectations of $13.99 billion. Demand for Pfizer's Prevnar 13 vaccine against pneumococcal bacteria fell because of wholesalers' purchasing patterns, the company said. Pfizer said it expected full-year earnings of $2.14 to $2.24 a share, down from its previous forecast of $2.20 to $2.30. It noted that the falling Japanese yen was hurting sales in that important market. Sales of Prevnar 13, the company's third-biggest product, fell 10 percent to $846 million. By contrast, sales of the vaccine used to prevent pneumonia and other infections had soared 19 percent in the prior quarter. Moreover, Pfizer said sales grew only 5 percent in emerging markets due in part to reduced government purchases of Prevnar 13 and of the company's Enbrel treatment for rheumatoid arthritis and psoriasis. Emerging market sales had jumped 17 percent in the prior quarter. Sales of generic medicines, which Pfizer calls established products and sells mainly overseas, fell 16 percent to $2.35 billion. That was also a reversal from the prior quarter, when they rose 3 percent. Sales of cholesterol fighter Lipitor, which has been competing with cheaper generics since November, plunged 55 percent to $626 million, while sales of impotence drug Viagra fell 7 percent to $461 million. The disappointing earnings report hit shares of Pfizer, which had risen 22 percent so far this year on high hopes for
Hot Net Payout Yield Stocks To Invest In 2015: United States Cellular Corporation(USM)
United States Cellular Corporation operates as a wireless telecommunications service provider in the United States. The company offers wireless voice and data services to retail consumer and business customers. It provides wireless services in postpaid service plans with voice, messaging, and data services; and prepaid service plans with minutes, messaging, and data services for a monthly fee. The company also offers various additional features, including caller ID blocking, call forwarding, voicemail, call waiting, and three-way calling; and data usage features consisting of Web browsing, email services, instant messaging, text messaging, and picture and video messaging. As of December 31, 2010, it provided wireless voice and data services to 6.1 million customers in 26 states. In addition, the company operates retail stores that sell a range of wireless devices, including handsets, modems, and tablets, as well as accessories, such as carrying cases, hands-free devices, b atteries, battery chargers, memory cards, and other items to consumers and small businesses. Further, it sells wireless devices to agents and other third-party distributors for resale; operates service facilities that provide servicing and repair for wireless devices; and enables customers to activate service and purchase wireless devices online. The company?s business customers include small-to-mid-size businesses in various industries, including construction, retail, professional services, and real estate. It offers its products and services through retail sales and service centers, direct sales, and independent agents. The company was founded in 1983 and is based in Chicago, Illinois. United States Cellular Corporation is a subsidiary of Telephone and Data Systems, Inc.
Advisors' Opinion: - [By Reuters]
Michael Sohn/APSprint CEO Dan Hesse Sprint has been ranked last among U.S. cellphone service operators in a customer satisfaction survey by the influential Consumer Reports organization, scoring dismal marks for measures ranging from voice to 4G reliability. No-frills carrier Consumer Cellular received the highest overall score of 88 out of 100, followed by U.S. Cellular (USM) with 75. Sprint received the lowest score of 59, faring the worst in terms of value, voice, text and 4G services. The annual ratings were based on a September survey of 58,399 cellphone service subscribers by the Consumer Reports National Research Center, which publishes widely followed surveys and reviews of everything from cars to refrigerators. In last year's survey, Sprint (S) trailed only Verizon Wireless among the four major carriers. Verizon Wireless (VZ) (VOD) ranked highest again this year with a score of 71. T-Mobile US (TMUS) rated 65 and AT&T (T) 64, according to survey results released Thursday. The rankings are based on ratings for voice, text and 4G, taking into account the occurrence of problems and adjusted for frequency of use. Sprint has been revamping its network after years of customer losses. The company, which is 80 percent owned by SoftBank, warned in October that customer defections would remain high in coming quarters. The company reported a decline in third-quarter revenue as it lost more subscribers than expected following the shutdown of its older network. "Our latest cell service satisfaction survey revealed a somewhat precipitous decline by Sprint that shuffled the rankings of the major standard service providers," Glenn Derene, Electronics Content Development Team Leader for Consumer Reports, said in a statement.
Mint made the Mac App Store's Best of 2012 list for a reason. This simple, clean app shows how much you are spending in each category of your budget by monitoring all of your transactions. We love signing in and getting a quick,
- [By Dan Radovsky]
T-Mobile US (NYSE: TMUS ) has agreed to purchase 10 MHz of Advanced Wireless Services spectrum from U.S. Cellular (NYSE: USM ) for $308 million, T-Mobile announced today.
- [By Jim Probasco]
CNET said it expects to see ZTE focus on premium quality smartphones at the Mobile World Congress at the end of February this year.�This would be a departure from the company�� previous concentration on mid-range priced phones offered by smaller carriers like Cricket Wireless, U.S. Cellular, (NYSE: USM) and Aio Wireless.
Hot Net Payout Yield Stocks To Invest In 2015: Akzo Nobel NV (AKZA)
Akzo Nobel NV is a manufacturer of paints, coatings and specialty chemicals based in the Netherlands. The Company operates within four segments. Within Buildings and Infrastructure segment, it manufactures decorative paints, protective, powder and coil coatings, and wood finishes for construction industry. Transportation segment offers specialty and powder coatings for automotive parts, peroxides, metal alkyls, and automotive, marine, yacht and aerospace coatings. Consumer Goods segment supplies finishes, adhesives and powder coatings for wood, specialty finishes for electronics, packaging coatings, surfactants, polymers and amines used in manufacture of soap, personal products and detergents. Within Industrial segment, it produces bulk chemicals, specialty chemicals, pulp and paper. In October 2013, it divested its Building Adhesives business; and acquired 50% stake and management control of Sadolin Paints Oman SAOC through joint venture agreement with Omar Zawawi Establishment LLC.
Advisors' Opinion: - [By Jonathan Morgan]
Akzo Nobel NV (AKZA) tumbled 8 percent to 43.52 euros, the biggest slide since 2008. Europe�� largest paintmaker reported a 14 percent decline in second-quarter earnings before interest, taxes, depreciation and amortization to 474 million euros. Sales fell 4 percent to 3.87 billion euros. Analysts had predicted 3.9 billion euros in revenue on average, based on estimates collated by Bloomberg.
Hot Net Payout Yield Stocks To Invest In 2015: Atlas Energy LP (ATLS)
Atlas Energy, L.P. (Atlas Energy), incorporated on December 15, 2005, is a limited partnership. The Company's assets consist of the Company's ownership interests in the Atlas Resource Partners, L.P. (ARP), an independent developer and producer of natural gas, crude oil and natural gas liquids (NGL), with operations in basins across the United States; Atlas Pipeline Partners, L.P. (APL) a midstream energy service provider engaged in natural gas gathering, processing and treating services in the Anandarko and Permian Basins of the United States, and Lightfoot Capital Partners, LP (Lightfoot LP) and Lightfoot Capital Partners GP, LLC (Lightfoot GP), the general partner of Lightfoot L.P. (collectively, Lightfoot), entities which incubate new master limited partnerships (MLPs) and invest in existing MLPs. As of December 31, 2012, the Company had an approximate 16% general partner interest and 12% limited partner interest in Lightfoot.
On April 30, 2012, ARP acquired 277 billion cubic feet equivalent of proved reserves, including undeveloped drilling locations, in the core of the Barnett Shale from Carrizo Oil & Gas, Inc. (Carrizo). The assets include 198 gross producing wells. On July 26, 2012, ARP acquired Titan Operating, L.L.C. (Titan), which owned approximately 250 billion cubic feet equivalent of proved reserves and associated assets in the Barnett Shale on approximately 16,000 net acres. Titan's assets are located in close proximity to the assets acquired from Carrizo in the Barnett Shale. On September 24, 2012, ARP acquired Equal Energy, Ltd�� (Equal) remaining 50% interest in approximately 8,500 net undeveloped acres. On December 20, 2012, ARP acquired 210 billion cubic feet equivalent of proved reserves in the Fort Worth basin from DTE Energy Company (DTE). The assets include 261 gross producing wells on over 88,000 net acres. The acreage position includes approximately 75,000 net acres prospective for the Marble Falls play, in which there are over 700 identified vertical drilling l! ocations..
In February 2012, APL acquired a gas gathering system and related assets, at its WestOK region. In June 2012, APL acquired a gas gathering system and related assets in the Barnett Shale in Tarrant County, Texas. In December 2012, APL acquired 100% interests held by Cardinal Midstream, LLC (Cardinal) in three wholly owned subsidiaries. The assets of these companies include gas gathering, processing and treating facilities in Arkansas, Louisiana, Oklahoma and Texas as the Tupelo plant, the East Rockpile treating facility, a fixed fee contract gas treating business, a 60% interest in Centrahoma Processing, LLC (Centrahoma), the Coalgate and Atoka plants, and the prospective Stonewall plant.
Atlas Resource Partners
During the year ended December 31, 2012, ARP�� average daily net production was approximately 77.2 million cubic feet equivalent. As of December 31, 2012, ARP owned production positions, including the Barnett Shale and Marble Falls play in the Fort Worth Basin in northern Texas; the Appalachia basin, including the Marcellus Shale and the Utica Shale; the Mississippi Lime and Hunton plays in northwestern Oklahoma, and the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan. ARP has ownership interests in over 525 wells in the Barnett Shale and Marble Falls play. ARP has ownership interests in over 10,200 wells in the Appalachian basin, including approximately 270 wells in the Marcellus Shale. The Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan.
Atlas Pipeline Partners
APL conducts its business in the midstream segment of the natural gas industry through two reportable segments: gathering and processing, and transportation, treating and other. The gathering and processing segment consist! s of the A! rkoma, WestOK, WestTX and Velma operations, which are comprised of natural gas gathering and processing assets servicing drilling activity in the Anadarko, Arkoma and Permian Basins, and natural gas gathering assets located in the Barnett Shale play in Texas and the Appalachian Basin in Tennessee. Gathering and processing revenues are derived from the sale of residue gas and NGLs and the gathering and processing of natural gas.
APL's gathering and processing operations, own, have interests in and operate 12 natural gas processing plants with aggregate capacity of approximately 1,090 million cubic feet per day located in Oklahoma and Texas; a gas treating facility located in Oklahoma, and approximately 10,100 miles of active natural gas gathering systems located in Oklahoma, Kansas, Tennessee and Texas. APL's gathering systems gather natural gas from oil and natural gas wells and central delivery points and deliver this gas to processing plants, as well as third-party pipelines.
APL's gathering and processing operations are located in Golden Trend, Mississippian Limestone and Hugoton field in the Anadarko Basin; the Woodford Shale; the Spraberry Trend, which is an oil play with associated natural gas in the Permian Basin, and the Barnett Shale. APL's gathering systems are connected to approximately 8,600 receipt points, consisting of individual well connections and secondarily, central delivery points, which are linked to multiple wells.
APL's transportation and treating operations consists of 17 gas treating facilities used to provide contract treating services to natural gas producers located in Arkansas, Louisiana, Oklahoma and Texas, and a 20% interest in West Texas LPG Pipeline Limited Partnership (WTLPG), which owns a common-carrier pipeline system, which transports NGLs from New Mexico and Texas to Mont Belvieu, Texas for fractionation. WTLPG is operated by Chevron Pipeline Company, an affiliate of Chevron Corporation (Chevron), which owns the remaining 80% i! nterest. ! The contract gas treating operations are located in various shale plays, including the Avalon, Eagle Ford, Granite Wash, Haynesville, Fayetteville and Woodford.
The Company competes with Access Midstream Partners, LP; Caballo Energy, LLC, Carrera Gas Company; Copano Energy, LLC; Crosstex Energy Services, L.P.; DCP Midstream, LLC; Energy Transfer Partners, LP.; Enogex, LLC; Lumen Midstream Partners, LLC; MarkWest Energy Partners, L.P.; Mustang Fuel Corporation; ONEOK Field Services Company, LLC; Scissor Tail Energy, LLC; SemGas, L.P.; Southern Union Company; Superior Pipeline Company, LLC; Targa Resources Partners LP, and West Texas Gas, Inc.
Advisors' Opinion:
